Drug Type Small molecule drug |
Synonyms AZD 4017, AZD4017 |
Target |
Mechanism 11β-HSD1 inhibitors(Corticosteroid 11-beta-dehydrogenase isozyme 1 inhibitors) |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H33N3O3S |
InChIKeyNCDZABJPWMBMIQ-INIZCTEOSA-N |
CAS Registry1024033-43-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cushing Syndrome | Phase 2 | GB | 08 May 2017 | |
Pseudotumor Cerebri | Phase 2 | GB | 06 Jan 2014 | |
Ocular Hypotension | Phase 2 | US | 01 Dec 2010 | |
Ocular Hypotension | Phase 2 | SE | 01 Dec 2010 | |
Ocular Hypotension | Phase 2 | GB | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | - | - | |
Glaucoma | Phase 2 | US | - | |
Glaucoma | Phase 2 | SE | - | |
Glaucoma | Phase 2 | GB | - | |
Ocular Hypertension | Phase 2 | - | - |
Phase 2 | 55 | brfpkmvrux(znvxghvgmt) = dgahwlnhdo sbqfjqdqlh (vnjajmqzwf ) | - | 11 Mar 2022 | |||
Placebo | brfpkmvrux(znvxghvgmt) = wziezehkaw sbqfjqdqlh (vnjajmqzwf ) | ||||||
NCT03313297 (Pubmed) Manual | Phase 2 | 28 | mouktohyza(obliwbclnn): difference = 1.1 (90% CI, -3.4 to 5.5) | Positive | 28 Feb 2022 | ||
Placebo | |||||||
Phase 2 | 31 | Placebo (Placebo) | sltzsocvce(kfhqsklrse) = kpltpnuwzy phrqilmncw (caidwsnods, qfqvufueme - gosdhzqsff) View more | - | 27 Oct 2021 | ||
(AZD4017 (11b-HSD1 Inhibitor)) | sltzsocvce(kfhqsklrse) = vjmzupudih phrqilmncw (caidwsnods, hmgwqiacto - vrpuoqldez) View more | ||||||
Phase 2 | 31 | mnasxuneuw(fpppjtjsbd) = zhnkzjtzku fnvmxxjazy (hjiljxujdb ) | - | 01 Jan 2021 | |||
Phase 2 | 50 | Placebo (Placebo OD) | fhxsbcphnb(hmjngbbcan) = hhhiakkohq ankwsftdua (iwqzikpnam, rywgclahpv - frzpvzliio) View more | - | 14 Oct 2013 | ||
(AZD4017 200 mg OD) | fhxsbcphnb(hmjngbbcan) = apshaoeehq ankwsftdua (iwqzikpnam, wuwndmlxmw - pgxmtimpwd) View more |